Inhibikase Therapeutics (IKT) Competitors $1.58 +0.02 (+1.28%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKT vs. REPL, CMPS, RGNX, ARCT, CMPX, ETON, ALMS, PRTA, CRVS, and ERASShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Replimune Group (REPL), COMPASS Pathways (CMPS), REGENXBIO (RGNX), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Eton Pharmaceuticals (ETON), Alumis (ALMS), Prothena (PRTA), Corvus Pharmaceuticals (CRVS), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors Replimune Group COMPASS Pathways REGENXBIO Arcturus Therapeutics Compass Therapeutics Eton Pharmaceuticals Alumis Prothena Corvus Pharmaceuticals Erasca Inhibikase Therapeutics (NYSE:IKT) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do analysts prefer IKT or REPL? Inhibikase Therapeutics currently has a consensus target price of $6.50, suggesting a potential upside of 311.39%. Replimune Group has a consensus target price of $6.50, suggesting a potential upside of 13.14%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Inhibikase Therapeutics is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Replimune Group 1 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.10 Which has more risk & volatility, IKT or REPL? Inhibikase Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Does the media prefer IKT or REPL? In the previous week, Replimune Group had 29 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 29 mentions for Replimune Group and 0 mentions for Inhibikase Therapeutics. Replimune Group's average media sentiment score of 0.18 beat Inhibikase Therapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media. Company Overall Sentiment Inhibikase Therapeutics Neutral Replimune Group Neutral Do insiders and institutionals have more ownership in IKT or REPL? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 5.2% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, IKT or REPL? Replimune Group is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.59Replimune GroupN/AN/A-$247.30M-$3.24-1.77 Is IKT or REPL more profitable? Replimune Group's return on equity of -69.34% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Replimune Group N/A -69.34%-52.81% SummaryInhibikase Therapeutics beats Replimune Group on 7 of the 13 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$117.74M$291.42M$5.73B$21.44BDividend YieldN/AN/A5.88%3.49%P/E Ratio-0.59N/A77.0329.81Price / SalesN/A422.15527.2151.35Price / CashN/A22.4437.2024.78Price / Book0.8910.3313.934.54Net Income-$19.03M-$111.61M$3.30B$999.97M7 Day Performance2.60%0.77%0.87%1.54%1 Month Performance-9.71%6.16%4.60%4.77%1 Year Performance36.21%-14.40%84.43%14.11% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics1.3196 of 5 stars$1.58+1.3%$6.50+311.4%+34.5%$117.74MN/A-0.596REPLReplimune Group3.8641 of 5 stars$6.04-4.6%$6.50+7.6%-44.6%$494.09MN/A-1.86210CMPSCOMPASS Pathways3.1899 of 5 stars$4.98-3.1%$16.29+227.0%-29.2%$493.14MN/A-2.71120Positive NewsRGNXREGENXBIO4.6094 of 5 stars$9.48-2.4%$28.38+199.3%-27.3%$490.49M$83.33M-2.76370Analyst RevisionARCTArcturus Therapeutics2.8769 of 5 stars$17.84-0.1%$50.57+183.5%-12.2%$484.72M$109.80M-8.00180News CoveragePositive NewsCMPXCompass Therapeutics2.2065 of 5 stars$3.44flat$12.89+274.7%+111.1%$475.69M$850K-7.6420Positive NewsETONEton Pharmaceuticals2.3045 of 5 stars$17.78+0.6%$29.67+66.9%+219.3%$473.87M$39.01M-111.1320Positive NewsALMSAlumis3.2624 of 5 stars$4.32-4.2%$20.17+366.8%-62.4%$469.33MN/A0.00N/APositive NewsPRTAProthena3.4303 of 5 stars$8.49-0.7%$19.75+132.6%-62.7%$460.25M$10.34M-1.51130News CoverageAnalyst RevisionCRVSCorvus Pharmaceuticals2.5 of 5 stars$5.90-4.2%$15.00+154.2%-0.7%$459.01MN/A-5.8430Positive NewsERASErasca2.3636 of 5 stars$1.55-3.7%$3.71+139.6%-39.4%$456.71MN/A-3.44120 Related Companies and Tools Related Companies REPL Alternatives CMPS Alternatives RGNX Alternatives ARCT Alternatives CMPX Alternatives ETON Alternatives ALMS Alternatives PRTA Alternatives CRVS Alternatives ERAS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts